HK Stock MarketDetailed Quotes
06160 BEIGENE
- 149.300
- +8.600+6.11%
Market Closed Oct 4 16:08 CST
206.11BMarket Cap-50405P/E (TTM)
151.900High140.100Low2.49MVolume144.000Open140.700Pre Close369.41MTurnover0.20%Turnover RatioLossP/E (Static)1.38BShares151.90052wk High7.84P/B188.93BFloat Cap75.45052wk Low--Dividend TTM1.27BShs Float278.600Historical High--Dividend LFY8.39%Amplitude61.050Historical Low148.653Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About BEIGENE Company
The company's mission is to become a global leader in the discovery, development and commercialization of innovative molecular-targeted immuno-oncology drugs to treat cancer. The company focuses on R&D, production and commercialization of innovative drugs. The main products are anti-tumor drugs, etc.
Company Profile
Symbol06160
Company NameBEIGENE
ISINKYG1146Y1017
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressCayman Islands
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young, Ernst & Young LLP, Ernst & Young AG, Ernst & Young AG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108, Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase 1, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees10000
MarketHong Kong motherboard
Phone+1 (781) 801-1800;1 (877) 828-5568
Fax010-85148699
Emailir@beigene.com
Websitehttp://www.beigene.com
BusinessBeiGene is a global, commercial-stage biotechnology company focused on the research, development, production and commercialization of innovative medicines.
Company Executives
- Name
- Position
- Salary
- leiqiang ou
- Presidencies, CEOs, Executive Director, Authorized Representative
- 16.74M
- xiaodong wang
- Non-executive Directors
- 4.27M
- Olivier Brandicourt
- Independent Non-Executive Director, Audit Committee Members
- --
- Margaret Han Dugan
- Independent Non-Executive Director, Remuneration Committee Chairman, Member of the Advisory Committee on Commercial and Medical Affairs
- 516.00K
- Donald W. Glazer
- Independent Non-Executive Director, Chairman of the Nomination and Corporate Governance Committee
- 486.00K
- Michael Goller
- Independent Non-Executive Director, Nomination and Corporate Governance Committee Members
- 487.00K
- Anthony C. Hooper
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- 518.00K
- Ranjeev Krishana
- Independent Non-Executive Director, Remuneration Committee Members
- 492.00K
- Shalini Sharp
- Independent Non-Executive Director, Audit Committee Members
- --
- Alessandro Riva
- Independent Non-Executive Director, Nomination Committee Members
- 497.00K
- Corazon (Corsee) D. Sanders
- Independent Non-Executive Director, Audit Committee Members
- 507.00K
- qingqing yi
- Independent Non-Executive Director, Remuneration Committee Members
- 492.00K
- xiaobin wu
- President, General Manager, Chief Operating Officer
- --
- Aaron Rosenberg
- Chief Financial Officer
- --
- lai wang
- Head of Global R&D
- --
- Chan Lee
- Senior Vice President, General Counsel
- --
- qingling zhou
- Authorized Representative, Company Secretary
- --
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data